First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

This study (HL-Russia-1) is evaluating first-line chemotherapy regimens for classic Hodgkin lymphoma in Russia — a blood cancer that affects the lymphatic system. The study follows patients through treatment and tracks outcomes to determine which approach works best. **You may be eligible if...** - You are 18–65 years old (note: the protocol states 18–5 years which appears to be a typo for 65) - You have a confirmed new diagnosis of classical Hodgkin lymphoma that has not been treated - Your general health and blood count values are in an acceptable range - You have access to a PET-CT scan facility - Your life expectancy is greater than 6 months **You may NOT be eligible if...** - You have a different subtype of Hodgkin lymphoma (nodular lymphocyte predominant) - You have had prior chemotherapy or radiation - You are pregnant or breastfeeding - You have significant heart problems (irregular rhythm, reduced pumping function, or coronary disease) - You have uncontrolled infection or HIV Talk to your doctor to see if this trial is right for you.